Moderate to Severe Asthma - Los Angeles CA

Summary:

A Phase IIB clinical research study evaluating the efficacy and safety of GB001, a once daily add-on pill, for adults with moderate to severe eosinophilic asthma

• 10 clinic visits over the course of 30-34 weeks

• Visit procedures can include physical exams, vital signs, electrocardiogram, breathing tests, exhaled nitric oxide tests, blood tests, pregnancy tests, urine sampling, and questionnaires 

• Once daily oral pill investigational treatment in addition to the asthma medications you are currently prescribed 

Qualified Participants Must:

• Be between 18 and 75 years of age at time of screening visit
• Have a body mass index (BMI) less than 40 kg/m₂ and weigh greater then or equal to 40 kg (88 lbs)
• Have a diagnosis of asthma by a physician of at least 12 months prior to screening
• Be prescribed a medium to high dose combination ICS + LABA (inhaled corticosteroid + long-acting beta agonist) therapy (e.g. Advair, Breo, Dulera, Symbicort, etc.) for at least 12 months prior to screening
• Have previously confirmed history of greater then or equal to 1 asthma exacerbation requiring treatment with systemic corticosteroids (e.g. Prednisone)
• Be committed to consistent and correct use of an acceptable method of birth control

Qualified Participants May Receive:

• Compensation up to $1,250 ($125 per visit), paid on the last business day of each month

• Reimbursement for any reasonable travel expenses
• No cost study-related treatment, study medication, and doctor consultations with 24hr emergency phone line